1.

Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.

1.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium ...

2.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium ...

3.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium ...

1.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium

2.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium

3.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium

4.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium

5.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium

1.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium.

2.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium.

3.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium.

1.

SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders : a prospective, real-life Belgian cohort study - the BELCOMID study

1.

The hepatitis C cascade of care in the Belgian HIV population: one step closer to elimination

1.

sj-docx-1-tam-10.1177_17588359231181500 – Supplemental material for A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic a...

2.

sj-docx-1-tam-10.1177_17588359231181500 – Supplemental material for A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic a...

3.

sj-docx-1-tam-10.1177_17588359231181500 – Supplemental material for A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic a...

1.

The hepatitis C cascade of care in the Belgian HIV population : one step closer to elimination

1.

The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination

2.

The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination

3.

The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination

4.

The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination

5.

The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination

1.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

2.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

3.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

4.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

5.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

6.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

7.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

8.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

9.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database